Australia's Noxopharm rises as novel cancer therapy shows potential

Noxopharm

26/05/2026 04:39

** Shares of Noxopharm NOX.AX rise as much as 58.3% to A$0.095, their biggest intraday pct gain since July 16, 2025

** The biotech firm announces new data that reflects how its Sofra technology platform will be leveraged to fight cancer

** Sofra focuses on the creation of a novel class of drugs targeting inflammatory and autoimmune diseases as well as enhancing RNA therapeutics and vaccines

** Says data supports a new and different approach to addressing significant unmet needs in cancer treatment, paving the way for a potentially highly disruptive new treatment modality

** More than 1.8 million shares change hands, 14.2 times the 30-day average

** Stock down 9.7% YTD, including the day's moves

 (Reporting by Nikita Maria Jino in Bengaluru)

 ((Nikita.Jino@thomsonreuters.com;))